Wuh-Liang Hwu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/808893/publications.pdf

Version: 2024-02-01

280 papers 9,434 citations

47006 47 h-index 83 g-index

287 all docs

287 docs citations

times ranked

287

9517 citing authors

#	Article	IF	CITATIONS
1	Clinical and molecular features of idiopathic hypogonadotropic hypogonadism in Taiwan: A single center experience. Journal of the Formosan Medical Association, 2022, 121, 218-226.	1.7	8
2	Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Molecular Therapy, 2022, 30, 509-518.	8.2	58
3	Outcome of Later-Onset Pompe Disease Identified Through Newborn Screening. Journal of Pediatrics, 2022, 244, 139-147.e2.	1.8	10
4	Advanced therapeutic strategy for hereditary neuromuscular diseases. Molecular Therapy, 2022, 30, 12-13.	8.2	1
5	Short stature leads to a diagnosis of Jansen–de Vries syndrome in two unrelated Taiwanese girls: A case report and literature review. Journal of the Formosan Medical Association, 2022, 121, 856-860.	1.7	2
6	Comparison of GATK and DeepVariant by trio sequencing. Scientific Reports, 2022, 12, 1809.	3.3	26
7	Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3. Molecular Genetics and Metabolism Reports, 2022, 31, 100867.	1.1	4
8	Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in Taiwan. Neurological Sciences, 2022, 43, 4563-4566.	1.9	13
9	Improved diagnosis of citrin deficiency by newborn screening using a molecular second-tier test. Molecular Genetics and Metabolism, 2022, 136, 330-336.	1.1	10
10	Thymidine Kinase 2 Deficiency–Induced Adult-Onset Ptosis and Proximal Weakness. Neurology: Clinical Practice, 2021, 11, e379-e382.	1.6	0
11	CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening. Genetics in Medicine, 2021, 23, 415-420.	2.4	13
12	STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa. Journal of Neurology, 2021, 268, 2482-2492.	3.6	21
13	Rapid Trio Exome Sequencing for Autosomal Recessive Renal Tubular Dysgenesis in Recurrent Oligohydramnios. Frontiers in Genetics, 2021, 12, 606970.	2.3	1
14	Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease. EMBO Molecular Medicine, 2021, 13, e14712.	6.9	17
15	Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma. Molecular Genetics and Metabolism, 2021, 133, 335-344.	1.1	12
16	Reduced Immunogenicity of Intraparenchymal Delivery of Adeno-Associated Virus Serotype 2 Vectors: Brief Overview. Current Gene Therapy, 2021, 21, .	2.0	2
17	A pilot study shows the positive effects of continuous airway pressure for treating hypernasal speech in children with infantile-onset Pompe disease. Scientific Reports, 2021, 11, 18826.	3.3	1
18	RNA-seq of peripheral blood mononuclear cells of congenital generalized lipodystrophy type 2 patients. Scientific Data, 2021, 8, 265.	5.3	3

#	Article	IF	CITATIONS
19	A novel deep intronic variant strongly associates with Alkaptonuria. Npj Genomic Medicine, 2021, 6, 89.	3.8	9
20	Molecular Analysis of Vietnamese Patients with Mucopolysaccharidosis Type I. Life, 2021, 11, 1162.	2.4	0
21	Novel Compound Heterozygous Variants in TBCD Gene Associated with Infantile Neurodegenerative Encephalopathy. Children, 2021, 8, 1140.	1.5	3
22	Thyroid disorders in Taiwanese children with Down syndrome: The experience of a single medical center. Journal of the Formosan Medical Association, 2020, 119, 345-349.	1.7	3
23	REM sleep and sleep apnea are associated with language function in Down syndrome children: An analysis of a community sample. Journal of the Formosan Medical Association, 2020, 119, 516-523.	1.7	14
24	Analysis of nondegraded and degraded DNA mixtures of close relatives using massively parallel sequencing. Legal Medicine, 2020, 42, 101631.	1.3	8
25	Early initiation of high-dose oral ambroxol in combination with enzyme replacement therapy in a neuropathic Gaucher infant. Blood Cells, Molecules, and Diseases, 2020, 81, 102402.	1.4	7
26	Cardiac manifestations and gene mutations of patients with RASopathies in Taiwan. American Journal of Medical Genetics, Part A, 2020, 182, 357-364.	1.2	8
27	Composite Scores of Plasma Tau and \hat{l}^2 -Amyloids Correlate with Dementia in Down Syndrome. ACS Chemical Neuroscience, 2020, 11, 191-196.	3.5	4
28	Ultrastructural and diffusion tensor imaging studies reveal axon abnormalities in Pompe disease mice. Scientific Reports, 2020, 10, 20239.	3.3	1
29	Survival and diagnostic age of 175 Taiwanese patients with mucopolysaccharidoses (1985–2019). Orphanet Journal of Rare Diseases, 2020, 15, 314.	2.7	16
30	Towards a reference genome that captures global genetic diversity. Nature Communications, 2020, 11, 5482.	12.8	34
31	Diversity in heritable disorders of connective tissue at a single center. Connective Tissue Research, 2020, 62, 1-6.	2.3	5
32	Frequency and spectrum of actionable pathogenic secondary findings in Taiwanese exomes. Molecular Genetics & Samp; Genomic Medicine, 2020, 8, e1455.	1.2	14
33	Dietary intake and nutritional status of patients with phenylketonuria in Taiwan. Scientific Reports, 2020, 10, 14537.	3.3	5
34	Lessons for the clinical nephrologist: dietary management of adult-onset type II citrullinemia in chronic kidney disease: a nutritional dilemma. Journal of Nephrology, 2020, 33, 1111-1113.	2.0	0
35	Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences. Molecular Genetics and Metabolism Reports, 2020, 23, 100591.	1.1	23
36	Complications of erythropoietin in navigated brain gene therapy: A case report. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2020, 21, 100698.	0.3	2

#	Article	IF	CITATIONS
37	Children Conceived by Assisted Reproductive Technology Prone to Low Birth Weight, Preterm Birth, and Birth Defects: A Cohort Review of More Than 50,000 Live Births During 2011–2017 in Taiwan. Frontiers in Pediatrics, 2020, 8, 87.	1.9	18
38	Clinical, radiological, and genetic characteristics in patients with Huntington's disease in a Taiwanese cohort. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2020, 183, 352-359.	1.7	1
39	De novo mutation and skewed Xâ€inactivation in girl with <i>BCAP31</i> â€related syndrome. Human Mutation, 2020, 41, 1775-1782.	2.5	3
40	Newborn screening for Morquio disease and other lysosomal storage diseases: results from the 8-plex assay for 70,000 newborns. Orphanet Journal of Rare Diseases, 2020, 15, 38.	2.7	40
41	Development of Newborn Screening for Pompe Disease. International Journal of Neonatal Screening, 2020, 6, 5.	3.2	2
42	The Timely Needs for Infantile Onset Pompe Disease Newborn Screeningâ€"Practice in Taiwan. International Journal of Neonatal Screening, 2020, 6, 30.	3.2	1
43	Primary coenzyme Q10 deficiency-7: expanded phenotypic spectrum and a founder mutation in southern Chinese. Npj Genomic Medicine, 2019, 4, 18.	3.8	29
44	Relationships among Height, Weight, Body Mass Index, and Age in Taiwanese Children with Different Types of Mucopolysaccharidoses. Diagnostics, 2019, 9, 148.	2.6	11
45	Functional independence of Taiwanese patients with mucopolysaccharidoses. Molecular Genetics & Samp; Genomic Medicine, 2019, 7, e790.	1.2	6
46	Heterogeneous nonataxic phenotypes of spinocerebellar ataxia in a Taiwanese population. Brain and Behavior, 2019, 9, e01414.	2.2	10
47	Genotypic and phenotypic correlations of biotinidase deficiency in the Chinese population. Orphanet Journal of Rare Diseases, 2019, 14, 6.	2.7	15
48	Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscular Disorders, 2019, 29, 842-856.	0.6	401
49	Clinical features of Pompe disease with motor neuronopathy. Neuromuscular Disorders, 2019, 29, 903-906.	0.6	7
50	Fabry disease cardiac variant IVS4+919 G>A is associated with multiple cardiac gene variants in patients with severe cardiomyopathy and fatal arrhythmia. Genetics in Medicine, 2019, 21, 1890-1891.	2.4	3
51	Reply to Lutz-Bonengel et al.: Biparental mtDNA transmission is unlikely to be the result of nuclear mitochondrial DNA segments. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1823-1824.	7.1	15
52	Mosaic paternal haploidy in a patient with pancreatoblastoma and Beckwith–Wiedemann spectrum. American Journal of Medical Genetics, Part A, 2019, 179, 1878-1883.	1.2	6
53	High incidence of coâ€existing GLA variants and stroke susceptibility. European Journal of Neurology, 2019, 26, e70-e70.	3.3	0
54	Gene therapy improves brain white matter in aromatic lâ€amino acid decarboxylase deficiency. Annals of Neurology, 2019, 85, 644-652.	5.3	30

#	Article	IF	Citations
55	Ophthalmologic manifestations in Taiwanese patients with mucopolysaccharidoses. Molecular Genetics & Camp; Genomic Medicine, 2019, 7, e00617.	1.2	13
56	Methylmalonic acidemia/propionic acidemia – the biochemical presentation and comparing the outcome between liver transplantation versus non-liver transplantation groups. Orphanet Journal of Rare Diseases, 2019, 14, 73.	2.7	26
57	Evaluation of dietary treatment and amino acid supplementation in organic acidurias and ureaâ€eycle disorders: On the basis of information from a European multicenter registry. Journal of Inherited Metabolic Disease, 2019, 42, 1162-1175.	3.6	30
58	Decreased plasma l-arginine levels in organic acidurias (MMA and PA) and decreased plasma branched-chain amino acid levels in urea cycle disorders as a potential cause of growth retardation: Options for treatment. Molecular Genetics and Metabolism, 2019, 126, 397-405.	1.1	26
59	Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients With Severe Illnesses*. Pediatric Critical Care Medicine, 2019, 20, 1021-1026.	0.5	29
60	Next-generation sequencing identifies TRPV4-related skeletal dysplasia in a boy with progressive bowlegs. Pediatrics and Neonatology, 2019, 60, 102-104.	0.9	3
61	A review of aromatic <scp> </scp> â€amino acid decarboxylase (AADC) deficiency in Taiwan. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2019, 181, 226-229.	1.6	12
62	Electrical Abnormalities in Dopaminergic Neurons of the Substantia Nigra in Mice With an Aromatic L-Amino Acid Decarboxylase Deficiency. Frontiers in Cellular Neuroscience, 2019, 13, 9.	3.7	3
63	Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD). Molecular Genetics and Metabolism, 2019, 126, 98-105.	1.1	56
64	Mycobacterium abscessus infection in a boy with X-linked anhidrotic ectodermal dysplasia, immunodeficiency. Journal of Microbiology, Immunology and Infection, 2019, 52, 504-506.	3.1	4
65	Long-term effects of enzyme replacement therapy for Taiwanese patients with mucopolysaccharidosis IVA. Pediatrics and Neonatology, 2019, 60, 342-343.	0.9	9
66	Congenital generalized lipodystrophy in Taiwan. Journal of the Formosan Medical Association, 2019, 118, 142-147.	1.7	11
67	Newborn screening: Taiwanese experience. Annals of Translational Medicine, 2019, 7, 281-281.	1.7	23
68	AGIL-AADC Gene Therapy Results in Sustained Improvements in Motor and Developmental Milestones over 5 Years in Children with AADC Deficiency. Neuropediatrics, 2019, 50, .	0.6	0
69	Comprehensive human leukocyte antigen genotyping of patients with type 1 diabetes mellitus in Taiwan. Pediatric Diabetes, 2018, 19, 699-706.	2.9	7
70	SHOX deficiency in short Taiwanese children: A single-center experience. Journal of the Formosan Medical Association, 2018, 117, 909-914.	1.7	6
71	Clinical characteristics of Taiwanese children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency detected by neonatal screening. Journal of the Formosan Medical Association, 2018, 117, 126-131.	1.7	10
72	A Neuron-Specific Gene Therapy Relieves Motor Deficits in Pompe Disease Mice. Molecular Neurobiology, 2018, 55, 5299-5309.	4.0	28

#	Article	IF	CITATIONS
73	Performance of the Four-Plex Tandem Mass Spectrometry Lysosomal Storage Disease Newborn Screening Test: The Necessity of Adding a 2nd Tier Test for Pompe Disease. International Journal of Neonatal Screening, 2018, 4, 41.	3.2	17
74	Biparental Inheritance of Mitochondrial DNA in Humans. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 13039-13044.	7.1	349
75	Results of Fabry Disease Screening in Male Pre-End Stage Renal Disease Patients with Unknown Etiology Found Through the Platform of a Chronic Kidney Disease Education Program in a Northern Taiwan Medical Center. Kidney and Blood Pressure Research, 2018, 43, 1636-1645.	2.0	23
76	Disease progression in a preâ€symptomatically treated patient with juvenileâ€onset Pompe disease – need for an earlier treatment?. European Journal of Neurology, 2018, 25, e111.	3.3	5
77	Mucopolysaccharidosis III in Taiwan: Natural history, clinical and molecular characteristics of 28 patients diagnosed during a 21â€year period. American Journal of Medical Genetics, Part A, 2018, 176, 1799-1809.	1.2	24
78	Clinical characteristics and surgical history of Taiwanese patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). Orphanet Journal of Rare Diseases, 2018, 13, 89.	2.7	10
79	Longitudinal follow-up to evaluate speech disorders in early-treated patients with infantile-onset Pompe disease. European Journal of Paediatric Neurology, 2017, 21, 485-493.	1.6	14
80	Gene therapy with modified U1 small nuclear RNA. Expert Review of Endocrinology and Metabolism, 2017, 12, 171-175.	2.4	5
81	Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease. Molecular Genetics and Metabolism Reports, 2017, 11, 31-35.	1.1	10
82	Genetic epidemiological study doesn't support GLA IVS4 \pm 919G > A variant is a significant mutation in Fabry disease. Molecular Genetics and Metabolism, 2017, 121, 22-27.	1.1	9
83	Natural History of Aromatic l-Amino Acid Decarboxylase Deficiency in Taiwan. JIMD Reports, 2017, 40, 1-6.	1.5	26
84	Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. The Lancet Child and Adolescent Health, 2017, 1, 265-273.	5.6	96
85	Presymptomatic Diagnosis of Spinal Muscular Atrophy Through Newborn Screening. Journal of Pediatrics, 2017, 190, 124-129.e1.	1.8	113
86	A Review of Biomarkers for Alzheimer's Disease in Down Syndrome. Neurology and Therapy, 2017, 6, 69-81.	3.2	19
87	Introduction to the Newborn Screening, Diagnosis, and Treatment for Pompe Disease Guidance Supplement. Pediatrics, 2017, 140, S1-S3.	2.1	11
88	Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum. Pediatrics, 2017, 140, S24-S45.	2.1	43
89	The Initial Evaluation of Patients After Positive Newborn Screening: Recommended Algorithms Leading to a Confirmed Diagnosis of Pompe Disease. Pediatrics, 2017, 140, S14-S23.	2.1	26
90	Newborn Screening for Severe Combined Immunodeficiency in Taiwan. International Journal of Neonatal Screening, 2017, 3, 16.	3.2	38

#	Article	IF	CITATIONS
91	Glypican-3 induces oncogenicity by preventing IGF-1R degradation, a process that can be blocked by Grb10. Oncotarget, 2017, 8, 80429-80442.	1.8	10
92	Slow, progressive myopathy in neonatally treated patients with infantile-onset Pompe disease: a muscle magnetic resonance imaging study. Orphanet Journal of Rare Diseases, 2016, 11, 63.	2.7	23
93	Causes of death and clinical characteristics of 34 patients with Mucopolysaccharidosis II in Taiwan from 1995–2012. Orphanet Journal of Rare Diseases, 2016, 11, 85.	2.7	26
94	3-O-methyldopa levels in newborns: Result of newborn screening for aromatic l-amino-acid decarboxylase deficiency. Molecular Genetics and Metabolism, 2016, 118, 259-263.	1.1	52
95	Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series. Molecular Genetics and Metabolism Reports, 2016, 7, 63-69.	1.1	27
96	Mutation-adapted U1 snRNA corrects a splicing error of the dopa decarboxylase gene. Human Molecular Genetics, 2016, 25, ddw323.	2.9	18
97	Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency. European Journal of Medicinal Chemistry, 2016, 123, 14-20.	5.5	15
98	Integrated care for Down syndrome. Congenital Anomalies (discontinued), 2016, 56, 104-106.	0.6	2
99	Advances in newborn screening for Pompe disease and resulting clinical outcomes. Expert Opinion on Orphan Drugs, 2016, 4, 21-29.	0.8	0
100	Hypothermia improves disease manifestations in SMA mice via SMN augmentation. Human Molecular Genetics, 2016, 25, 631-641.	2.9	5
101	Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI. Molecular Genetics and Metabolism, 2016, 117, 431-437.	1.1	37
102	Long-term outcome for Down syndrome patients with hematopoietic disorders. Journal of the Formosan Medical Association, 2016, 115, 94-99.	1.7	5
103	Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer's Disease. Frontiers in Aging Neuroscience, 2016, 8, 316.	3.4	44
104	Mudd's disease (MAT I/III deficiency): a survey of data for MAT1A homozygotes and compound heterozygotes. Orphanet Journal of Rare Diseases, 2015, 10, 99.	2.7	39
105	Congenital Malformations in Newborns—A Challenge Unmet for Decades. Pediatrics and Neonatology, 2015, 56, 5-6.	0.9	0
106	Long-Term Prognosis of Patients with Infantile-Onset Pompe Disease Diagnosed by Newborn Screening and Treated since Birth. Journal of Pediatrics, 2015, 166, 985-991.e2.	1.8	113
107	Benefits of Neuronal Preferential Systemic Gene Therapy for Neurotransmitter Deficiency. Molecular Therapy, 2015, 23, 1572-1581.	8.2	25
108	Mortality, disability, and intensive care in patients with mitochondrial 3243A>G mutation. Intensive Care Medicine, 2015, 41, 1493-1495.	8.2	1

#	Article	IF	Citations
109	Incidence of severe combined immunodeficiency through newborn screening in a Chinese population. Journal of the Formosan Medical Association, 2015, 114, 12-16.	1.7	68
110	A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4–7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. Genetics in Medicine, 2014, 16, 435-441.	2.4	29
111	Systemic Administration of a Recombinant AAV1 Vector Encoding IGF-1 Improves Disease Manifestations in SMA Mice. Molecular Therapy, 2014, 22, 1450-1459.	8.2	42
112	Hypertrophic Cardiomyopathy in Pompe Disease Is Not Limited to the Classic Infantile-Onset Phenotype. JIMD Reports, 2014, 17, 71-75.	1.5	30
113	Baseline Urinary Glucose Tetrasaccharide Concentrations in Patients with Infantile- and Late-Onset Pompe Disease Identified by Newborn Screening. JIMD Reports, 2014, 19, 67-73.	1.5	29
114	Treatment of Congenital Neurotransmitter Deficiencies by Intracerebral Ventricular Injection of an Adeno-Associated Virus Serotype 9 Vector. Human Gene Therapy, 2014, 25, 189-198.	2.7	19
115	Prominent vacuolation of the eyelid levator muscle in an earlyâ€treated child with infantileâ€onset Pompe disease. Muscle and Nerve, 2014, 50, 301-302.	2.2	7
116	Parental discussion of G6PD deficiency and child health: implications for clinical practice. Archives of Disease in Childhood, 2014, 99, 251-255.	1.9	1
117	Cyclic Pamidronate Infusion for Neonatal-onset Osteogenesis Imperfecta. Pediatrics and Neonatology, 2014, 55, 306-311.	0.9	11
118	The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients. Acta Neuropathologica Communications, 2014, 2, 2.	5.2	55
119	Efficacy and safety of intermittent hemodialysis in infants and young children with inborn errors of metabolism. Pediatric Nephrology, 2014, 29, 111-116.	1.7	16
120	Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA. Orphanet Journal of Rare Diseases, 2014, 9, 21.	2.7	25
121	Diagnosis of aromatic l-amino acid decarboxylase deficiency by measuring 3-O-methyldopa concentrations in dried blood spots. Clinica Chimica Acta, 2014, 431, 19-22.	1.1	29
122	Outcome of early-treated type III Gaucher disease patients. Blood Cells, Molecules, and Diseases, 2014, 53, 105-109.	1.4	22
123			

#	Article	IF	Citations
127	Lysoâ€globotriaosylsphingosine (lysoâ€Gb ₃) levels in neonates and adults with the Fabry disease laterâ€onset <i>GLA</i> IVS4+919G>A mutation. Journal of Inherited Metabolic Disease, 2013, 36, 881-885.	3.6	18
128	Regulation of the dopaminergic system in a murine model of aromatic l-amino acid decarboxylase deficiency. Neurobiology of Disease, 2013, 52, 177-190.	4.4	37
129	Pompe Disease: Early Diagnosis and Early Treatment Make a Difference. Pediatrics and Neonatology, 2013, 54, 219-227.	0.9	135
130	AADC Deficiency. Advances in Pharmacology, 2013, 68, 273-284.	2.0	10
131	Carnitine Uptake Defect (Primary Carnitine Deficiency): Risk in Genotype-Phenotype Correlation. Human Mutation, 2013, 34, 655-655.	2.5	13
132	Longâ€ŧerm efficacy of miglustat in paediatric patients with Niemannâ€Pick disease type C. Journal of Inherited Metabolic Disease, 2013, 36, 129-137.	3.6	34
133	Lung toxicity of hydroxypropyl- \hat{l}^2 -cyclodextrin infusion. Molecular Genetics and Metabolism, 2013, 109, 231-232.	1.1	27
134	Diagnosing mucopolysaccharidosis IVA. Journal of Inherited Metabolic Disease, 2013, 36, 293-307.	3.6	77
135	Clinical application of massively parallel sequencing in the molecular diagnosis of glycogen storage diseases of genetically heterogeneous origin. Genetics in Medicine, 2013, 15, 106-114.	2.4	65
136	Fatty Acid Oxidation Disorders in a Chinese Population in Taiwan. JIMD Reports, 2013, 11, 165-172.	1.5	26
137	Analysis of Lyso-Globotriaosylsphingosine in Dried Blood Spots. Annals of Laboratory Medicine, 2013, 33, 274-278.	2.5	29
138	Myostatin and Insulin-Like Growth Factor I: Potential Therapeutic Biomarkers for Pompe Disease. PLoS ONE, 2013, 8, e71900.	2.5	15
139	Web-Based Newborn Screening System for Metabolic Diseases: Machine Learning Versus Clinicians. Journal of Medical Internet Research, 2013, 15, e98.	4.3	19
140	Enhanced interpretation of newborn screening results without analyte cutoff values. Genetics in Medicine, 2012, 14, 648-655.	2.4	117
141	Association of the Congenital Neuromuscular Form of Glycogen Storage Disease Type IV With a Large Deletion and Recurrent Frameshift Mutation. Journal of Child Neurology, 2012, 27, 204-208.	1.4	15
142	Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer. Journal of Human Genetics, 2012, 57, 130-138.	2.3	21
143	Newborn Screening for Phenylketonuria: Machine Learning vs Clinicians. , 2012, , .		1
144	Diagnosis of Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency Using High-Resolution Melting Analysis and a Clinical Scoring System. Journal of Pediatrics, 2012, 161, 626-631.e2.	1.8	14

#	Article	IF	Citations
145	Current diagnosis and management of mucopolysaccharidosis VI in the Asia-Pacific region. Molecular Genetics and Metabolism, 2012, 107, 136-144.	1.1	6
146	Late onset of symptoms in an atypical patient with the cblJ inborn error of vitamin B12 metabolism: Diagnosis and novel mutation revealed by exome sequencing. Molecular Genetics and Metabolism, 2012, 107, 664-668.	1.1	33
147	Early Pathologic Changes and Responses to Treatment in Patients With Later-Onset Pompe Disease. Pediatric Neurology, 2012, 46, 168-171.	2.1	21
148	Algorithm for Pompe disease newborn screening: Results from the Taiwan screening program. Molecular Genetics and Metabolism, 2012, 106, 281-286.	1.1	72
149	An acidic oligopeptide displayed on AAV2 improves axial muscle tropism after systemic delivery. Genetic Vaccines and Therapy, 2012, 10, 3.	1.5	4
150	A Novel 3670-Base Pair Mitochondrial DNA Deletion Resulting in Multi-systemic Manifestations in a Child. Pediatrics and Neonatology, 2012, 53, 264-268.	0.9	15
151	Can a girl with 3-hydroxy-3-methylglutaryl-CoA lyase deficiency live a normal life?. Tzu Chi Medical Journal, 2012, 24, 215-217.	1.1	0
152	Application of Mass Spectrometry in Newborn Screening: About Both Small Molecular Diseases and Lysosomal Storage Diseases. Topics in Current Chemistry, 2012, 336, 177-196.	4.0	5
153	Genome-Wide Gene Expression Analysis Implicates the Immune Response and Lymphangiogenesis in the Pathogenesis of Fetal Chylothorax. PLoS ONE, 2012, 7, e34901.	2.5	12
154	Fabry Disease: Incidence of the Common Later-Onset α-Galactosidase A IVS4+919G→A Mutation in Taiwanese Newborns—Superiority of DNA-Based to Enzyme-Based Newborn Screening for Common Mutations. Molecular Medicine, 2012, 18, 780-784.	4.4	71
155	Gene Therapy for Aromatic <scp>l</scp> -Amino Acid Decarboxylase Deficiency. Science Translational Medicine, 2012, 4, 134ra61.	12.4	195
156	Mutation screening of the <i>EYA1, SIX1</i> , and <i>SIX5</i> genes in an east asian cohort with branchioâ€otoâ€renal syndrome. Laryngoscope, 2012, 122, 1130-1136.	2.0	25
157	Integrating Human Genome Database into Electronic Health Record with Sequence Alignment and Compression Mechanism. Journal of Medical Systems, 2012, 36, 2587-2597.	3.6	7
158	PSORS2 Is Due to Mutations in CARD14. American Journal of Human Genetics, 2012, 90, 784-795.	6.2	365
159	IGF-1 delivery to CNS attenuates motor neuron cell death but does not improve motor function in type III SMA mice. Neurobiology of Disease, 2012, 45, 272-279.	4.4	41
160	Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project. Genetics in Medicine, 2011, 13, 230-254.	2.4	308
161	Left Ventricular Geometry, Global Function, and Dyssynchrony in Infants and Children With Pompe Cardiomyopathy Undergoing Enzyme Replacement Therapy. Journal of Cardiac Failure, 2011, 17, 930-936.	1.7	25
162	Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Human Molecular Genetics, 2011, 20, 4851-4864.	2.9	129

#	Article	IF	CITATIONS
163	Distribution, clinical features and treatment in Taiwanese patients with symptomatic primary immunodeficiency diseases (PIDs) in a nationwide population-based study during 1985–2010. Immunobiology, 2011, 216, 1286-1294.	1.9	51
164	Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease. Molecular Genetics and Metabolism, 2011, 102, 57-60.	1.1	9
165	Rapid progressive course of later-onset Pompe disease in Chinese patients. Molecular Genetics and Metabolism, 2011, 104, 284-288.	1.1	39
166	The use of dried blood spot samples in the diagnosis of lysosomal storage disorders — Current status and perspectives. Molecular Genetics and Metabolism, 2011, 104, 144-148.	1.1	69
167	Preimplantation and prenatal genetic diagnosis of aromatic L-amino acidÂdecarboxylase deficiency with an amplification refractory mutation system-quantitative polymerase chain reaction. Taiwanese Journal of Obstetrics and Gynecology, 2011, 50, 468-473.	1.3	13
168	Congenital Hypopituitarism due to POU1F1 Gene Mutation. Journal of the Formosan Medical Association, 2011, 110, 58-61.	1.7	10
169	Later-Onset Pompe Disease: Early Detection and Early Treatment Initiation Enabled by Newborn Screening. Journal of Pediatrics, 2011, 158, 1023-1027.e1.	1.8	88
170	CEREBRAL DIFFUSION TENSOR IMAGES IN INFANTS AND NEONATES WITH INFANTILE ONSET POMPE DISEASE. Biomedical Engineering - Applications, Basis and Communications, 2011, 23, 205-213.	0.6	2
171	Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. Journal of Inherited Metabolic Disease, 2010, 33, 295-305.	3.6	128
172	Newborn screening for neuropathic lysosomal storage disorders. Journal of Inherited Metabolic Disease, 2010, 33, 381-386.	3.6	20
173	Complex rearrangements between chromosomes 6, 10, and 11 with multiple deletions at breakpoints. American Journal of Medical Genetics, Part A, 2010, 152A, 2327-2334.	1.2	14
174	Stabilization of blood methylmalonic acid level in methylmalonic acidemia after liver transplantation. Pediatric Transplantation, 2010, 14, 337-341.	1.0	35
175	Phenotypic Analyses and Mutation Screening of the <i>SLC26A4</i> and <i>FOXI1</i> Genes in 101 Taiwanese Families with Bilateral Nonsyndromic Enlarged Vestibular Aqueduct (DFNB4) or Pendred Syndrome. Audiology and Neuro-Otology, 2010, 15, 57-66.	1.3	60
176	Screening Assay of Very Long Chain Fatty Acids in Human Plasma with Multiwalled Carbon Nanotube-Based Surface-Assisted Laser Desorption/Ionization Mass Spectrometry. Analytical Chemistry, 2010, 82, 6814-6820.	6.5	50
177	Enzyme replacement therapy for mucopolysaccharidosis VI—experience in Taiwan. Journal of Inherited Metabolic Disease, 2010, 33, 421-427.	3.6	59
178	CCL18 as an alternative marker in Gaucher and Niemann-Pick disease with chitotriosidase deficiency. Blood Cells, Molecules, and Diseases, 2010, 44, 38-40.	1.4	15
179	Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry. Clinica Chimica Acta, 2010, 411, 1428-1431.	1.1	47
180	How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?. Clinica Chimica Acta, 2010, 411, 1906-1914.	1.1	94

#	Article	IF	Citations
181	Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Molecular Genetics and Metabolism, 2010, 99, 379-383.	1.1	91
182	Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening. Molecular Genetics and Metabolism, 2010, 100, 46-50.	1.1	86
183	Reduction in imiglucerase dosage causes immediate rise of chitotriosidase activity in patients with Gaucher disease. Molecular Genetics and Metabolism, 2010, 101, 90-91.	1.1	2
184	Enzymatic activity of methionine adenosyltransferase variants identified in patients with persistent hypermethioninemia. Molecular Genetics and Metabolism, 2010, 101, 172-177.	1.1	28
185	Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Molecular Genetics and Metabolism, 2010, 101, 324-331.	1.1	69
186	Newborn Screening for Methylmalonic Aciduria by Tandem Mass Spectrometry: 7 Years' Experience From Two Centers in Taiwan. Journal of the Chinese Medical Association, 2010, 73, 314-318.	1.4	15
187	A validated disease severity scoring system for adults with type 1 Gaucher disease. Genetics in Medicine, 2010, 12, 44-51.	2.4	66
188	FOXL2 mutations in Taiwanese patients with blepharophimosis, ptosis, epicanthus inversus syndrome. Clinical Chemistry and Laboratory Medicine, 2010, 48, 485-8.	2.3	6
189	Correlation of Survival Motor Neuron Expression in Leukocytes and Spinal Cord in Spinal Muscular Atrophy. Journal of Pediatrics, 2009, 154, 303-305.	1.8	9
190	Reversal of Cardiac Dysfunction after Enzyme Replacement in Patients with Infantile-Onset Pompe Disease. Journal of Pediatrics, 2009, 155, 271-275.e2.	1.8	56
191	Caloric restriction in Alström syndrome prevents hyperinsulinemia. American Journal of Medical Genetics, Part A, 2009, 149A, 666-668.	1.2	16
192	Incidence of the mucopolysaccharidoses in Taiwan, 1984–2004. American Journal of Medical Genetics, Part A, 2009, 149A, 960-964.	1.2	145
193	Somatic and germâ€line mosaicism in Rubinstein–Taybi syndrome. American Journal of Medical Genetics, Part A, 2009, 149A, 1463-1467.	1.2	40
194	Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset <i>GLA</i> mutation c.936+919G>A (IVS4+919G>A). Human Mutation, 2009, 30, 1397-1405.	2.5	299
195	Application of SNaPshot multiplex assays for simultaneous multigene mutation screening in patients with idiopathic sensorineural hearing impairment. Laryngoscope, 2009, 119, 2411-2416.	2.0	18
196	Cryptic subtelomeric deletion plus inverted duplication at chromosome 18q in a fetus: molecular delineation by multicolor banding. Prenatal Diagnosis, 2009, 29, 1058-1060.	2.3	6
197	Hyperammonemia and positive allopurinol test in hyperinsulinism–hyperammonemia syndrome: Taiwanese case report. Pediatrics International, 2009, 51, 305-307.	0.5	0
198	Pseudogeneâ€derived <i>IKBKG</i> gene mutations in incontinentia pigmenti. Clinical Genetics, 2009, 76, 417-419.	2.0	6

#	Article	IF	Citations
199	Cystathionine Î ³ -lyase: Clinical, metabolic, genetic, and structural studies. Molecular Genetics and Metabolism, 2009, 97, 250-259.	1.1	57
200	Schizencephaly in LEOPARD Syndrome. Pediatric Neurology, 2009, 41, 71-73.	2.1	4
201	Glycogen Storage Disease Type Ib: The First Case in Taiwan. Pediatrics and Neonatology, 2009, 50, 125-128.	0.9	3
202	X-linked Liver Glycogenosis in a Taiwanese Family: Transmission From Undiagnosed Males. Pediatrics and Neonatology, 2009, 50, 230-233.	0.9	6
203	Pompe Disease in Infants: Improving the Prognosis by Newborn Screening and Early Treatment. Pediatrics, 2009, 124, e1116-e1125.	2.1	185
204	Bone marrow transplantation results in donor-derived hepatocytes in an animal model of inherited cholestatic liver disease. Journal of Biomedical Science, 2008, 15, 615-622.	7.0	7
205	Long-term follow-up of a girl with Maroteaux-Lamy syndrome after bone marrow transplantation. World Journal of Pediatrics, 2008, 4, 152-154.	1.8	19
206	Acute metabolic decompensation and sudden death in Barth syndrome: report of a family and a literature review. European Journal of Pediatrics, 2008, 167, 941-944.	2.7	47
207	A Promoter Sequence Variant of ZNF750 Is Linked with Familial Psoriasis. Journal of Investigative Dermatology, 2008, 128, 1662-1668.	0.7	35
208	Torsade de pointes ventricular tachycardia during elective intubation in a patient with Pompe disease. Paediatric Anaesthesia, 2008, 18, 346-348.	1.1	7
209	Mitral annuloplasty in an infant with Barth syndrome and severe mitral insufficiency: First case report and determination of annular diameter. Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 1095-1097.	0.8	4
210	Mutation of Mitochondrial DNA G13513A Presenting with Leigh Syndrome, Wolff-Parkinson-White Syndrome and Cardiomyopathy. Pediatrics and Neonatology, 2008, 49, 145-149.	0.9	52
211	Brain Damage by Mild Metabolic Derangements in Methylmalonic Acidemia. Pediatric Neurology, 2008, 39, 325-329.	2.1	24
212	Hsp27 decreases inclusion body formation from mutated GTP-cyclohydrolase I protein. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 169-179.	3.8	2
213	Genetic analysis of mucopolysaccharidosis type VI in Taiwanese patients. Clinica Chimica Acta, 2008, 394, 89-93.	1.1	23
214	Screening of Newborns for Pompe Disease and/or Other Lysosomal Storage Disorders. Clinical Therapeutics, 2008, 30, S8.	2.5	0
215	Alglucosidase Alfa (Myozyme $\hat{A}^{\text{@}}$) in Infants and Children with Rapidly Progressive Pompe Disease. Clinical Therapeutics, 2008, 30, S9-S10.	2.5	0
216	Early Detection of Glutaric Aciduria Type I by Newborn Screening in Taiwan. Journal of the Formosan Medical Association, 2008, 107, 139-144.	1.7	18

#	Article	IF	Citations
217	Early Detection of Pompe Disease by Newborn Screening Is Feasible: Results From the Taiwan Screening Program. Pediatrics, 2008, 122, e39-e45.	2.1	207
218	Fibrous Dysplasia in a Child with Mitochondrial A8344G Mutation. Journal of Child Neurology, 2008, 23, 1447-1450.	1.4	8
219	Myopathy in Gaucher disease. Journal of Inherited Metabolic Disease, 2008, 31, 489-491.	3.6	4
220	Chubby Face and the Biochemical Parameters for the Early Diagnosis of Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency. Journal of Pediatric Gastroenterology and Nutrition, 2008, 47, 187-192.	1.8	19
221	Newborn Screening for Pompe Disease: Synthesis of the Evidence and Development of Screening Recommendations. Pediatrics, 2007, 120, e1327-e1334.	2.1	53
222	Copy number analysis of survival motor neuron genes by multiplex ligation-dependent probe amplification. Genetics in Medicine, 2007, 9, 241-248.	2.4	58
223	Lack of mutations in spinocerebellar ataxia type 2 and 3 genes in a Taiwanese (ethnic Chinese) cohort of familial and early-onset parkinsonism. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 434-438.	1.7	8
224	Identification and management of cardiac perforation from a double lumen catheter in an infant. Paediatric Anaesthesia, 2007, 17, 500-502.	1.1	2
225	Outcome of pulmonary and aortic stenosis in Williamsâ€Beuren syndrome in an Asian cohort. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 906-909.	1.5	33
226	Deficiency of the carnitine transporter (OCTN2) with partial N-acetylglutamate synthase (NAGS) deficiency. Journal of Inherited Metabolic Disease, 2007, 30, 816-816.	3.6	11
227	Treatment of Niemann–Pick disease type C in two children with miglustat: Initial responses and maintenance of effects over 1Âyear. Journal of Inherited Metabolic Disease, 2007, 30, 826-826.	3.6	42
228	The Genetics of Atopic Dermatitis. Clinical Reviews in Allergy and Immunology, 2007, 33, 178-190.	6.5	25
229	A review of treatment of Pompe disease in infants. Biologics: Targets and Therapy, 2007, 1, 195-201.	3.2	7
230	Tandem Mass Neonatal Screening in Taiwan—Report from One Center. Journal of the Formosan Medical Association, 2006, 105, 882-886.	1.7	32
231	Homozygous SLC25A13 Mutation in a Taiwanese Patient with Adult-onset Citrullinemia Complicated with Steatosis and Hepatocellular Carcinoma. Journal of the Formosan Medical Association, 2006, 105, 852-856.	1.7	30
232	Mutation analysis of Gaucher disease patients in Taiwan: High prevalence of the RecNcil and L444P mutations. Blood Cells, Molecules, and Diseases, 2006, 36, 422-425.	1.4	47
233	A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. Journal of Pediatrics, 2006, 148, 671-676.e2.	1.8	500
234	Hepatic steatosis and neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) in Taiwanese infants. Journal of Pediatrics, 2006, 148, 642-646.	1.8	37

#	Article	IF	Citations
235	Time course of acylcarnitine elevation in neonatal intrahepatic cholestasis caused by citrin deficiency. Journal of Inherited Metabolic Disease, 2006, 29, 551-555.	3.6	17
236	Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiology of Disease, 2006, 24, 286-295.	4.4	54
237	Brain Development in Infantile-Onset Pompe Disease Treated by Enzyme Replacement Therapy. Pediatric Research, 2006, 60, 349-352.	2.3	75
238	Reye's syndrome developing in an infant on treatment of Kawasaki syndrome. Journal of Paediatrics and Child Health, 2005, 41, 303-304.	0.8	29
239	Spectrum of hypermethioninemia in neonatal screening. Early Human Development, 2005, 81, 529-533.	1.8	32
240	Prevalence of the FMR1 mutation in Taiwan assessed by large-scale screening of newborn boys and analysis of DXS548-FRAXAC1 haplotype. American Journal of Medical Genetics, Part A, 2005, 133A, 37-43.	1.2	53
241	Type I Gaucher disease with exophthalmos and pulmonary arteriovenous malformation. BMC Medical Genetics, 2005, 6, 25.	2.1	3
242	Mapping of psoriasis to 17q terminus. Journal of Medical Genetics, 2005, 42, 152-158.	3.2	38
243	Parkin Mutations and Early-Onset Parkinsonism in a Taiwanese Cohort. Archives of Neurology, 2005, 62, 82.	4.5	84
244	Fundus abnormalities in a patient with type I Gaucher's disease with 12-year follow-up. American Journal of Ophthalmology, 2005, 139, 359-362.	3.3	14
245	Adenoviral interneuronal transportation after retrograde gene transfer in mice. Molecular Brain Research, 2005, 142, 151-155.	2.3	3
246	Poor Outcome for Neonatal-Type Nonketotic Hyperglycinemia Treated With High-Dose Sodium Benzoate and Dextromethorphan. Journal of Child Neurology, 2004, 19, 39-42.	1.4	48
247	Detection of a homozygous D645E mutation of the acidl±-glucosidase gene and glycogen deposition in tissues in a second-trimester fetus with infantile glycogen storage disease type II. Prenatal Diagnosis, 2004, 24, 231-232.	2.3	12
248	Molecular chaperones affect GTP cyclohydrolase I mutations in dopa-responsive dystonia. Annals of Neurology, 2004, 55, 875-878.	5.3	10
249	Mutation spectrum in Taiwanese patients with phenylalanine hydroxylase deficiency and a founder effect for the R241C mutation. Human Mutation, 2004, 23, 206-206.	2.5	28
250	Molecular diagnosis of Wiskott-Aldrich syndrome in Taiwan. Journal of Microbiology, Immunology and Infection, 2004, 37, 276-81.	3.1	5
251	Phenylalanine hydroxylase deficiency: intelligence of patients after early dietary treatment. Acta Paediatrica Taiwanica = Taiwan Er Ke Yi Xue Hui Za Zhi, 2004, 45, 320-3.	0.1	2
252	Regulation of GTP cyclohydrolase I by alternative splicing in mononuclear cells. Biochemical and Biophysical Research Communications, 2003, 306, 937-942.	2.1	12

#	Article	IF	Citations
253	Screening of nine SLC25A13 mutations: their frequency in patients with citrin deficiency and high carrier rates in Asian populations. Molecular Genetics and Metabolism, 2003, 80, 356-359.	1.1	69
254	Gene symbol: OTC. Disease: ornithine carbamoyltransferase deficiency. Human Genetics, 2003, 113, 365.	3.8	2
255	Gene symbol: OTC. Disease: ornithine carbamoyltransferase deficiency. Human Genetics, 2003, 113, 367.	3.8	2
256	Neonatal screening and monitoring system in Taiwan. Southeast Asian Journal of Tropical Medicine and Public Health, 2003, 34 Suppl 3, 91-3.	1.0	2
257	Spontaneous chylothorax in a case of cardio-facio-cutaneous syndrome. Clinical Dysmorphology, 2002, 11, 297-298.	0.3	6
258	Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations. Movement Disorders, 2002, 17, 670-675.	3.9	44
259	Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant. Journal of Inherited Metabolic Disease, 2002, 25, 593-595.	3.6	10
260	Cranial MR spectroscopy of tetrahydrobiopterin deficiency. American Journal of Neuroradiology, 2002, 23, 1055-8.	2.4	11
261	Neonatal screening for congenital adrenal hyperplasia in Taiwan: a pilot study. Journal of the Formosan Medical Association, 2002, 101, 691-4.	1.7	11
262	Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease. Journal of the Formosan Medical Association, 2002, 101, 627-31.	1.7	5
263	Cloning of Dimethylglycine Dehydrogenase and a New Human Inborn Error of Metabolism, Dimethylglycine Dehydrogenase Deficiency. American Journal of Human Genetics, 2001, 68, 839-847.	6.2	66
264	Molecular Genetics of Glycogen-Storage Disease Type 1a in Chinese Patients of Taiwan. Molecular Genetics and Metabolism, 2001, 72, 175-180.	1.1	16
265	Deletion of 11q24.2-qter with agenesis of unilateral internal carotid artery and total anomalous pulmonary venous return. American Journal of Medical Genetics Part A, 2001, 103, 245-248.	2.4	7
266	Treatment and outcome of Taiwanese patients with 6-pyruvoyltetrahydropterin synthase gene mutations. Journal of Inherited Metabolic Disease, 2001, 24, 815-823.	3.6	27
267	Dopa-responsive dystonia is induced by a dominant-negative mechanism. Annals of Neurology, 2000, 48, 609-613.	5.3	48
268	Allele distribution at the FMR1 locus in the general Chinese population. Clinical Genetics, 1999, 55, 353-356.	2.0	12
269	Molecular genetic study of Pompe disease in Chinese patients in Taiwan. Human Mutation, 1999, 13, 380-384.	2.5	58
270	Homozygous mutation 341delG/101X of the glucose-6-phosphatase (G6PC) gene causes glycogen storage disease type Ia (von Gierke disease) in a Chinese patient. Human Mutation, 1999, 13, 414-414.	2.5	0

#	Article	IF	CITATIONS
271	Neonatal type of nonketotic hyperglycinemia. Pediatric Neurology, 1999, 20, 295-300.	2.1	37
272	Two common mutations 934C to G and 937C to G of fibroblast growth factor receptor 2 (FGFR2) gene in Chinese patients with apert syndrome. Human Mutation, 1998 , 11 , $18-19$.	2.5	5
273	Linkage disequilibrium and linkage analysis of the glucose-6-phosphatase gene. Human Genetics, 1998, 103, 199-203.	3.8	11
274	The controversy regarding diagnostic criteria for early myoclonic encephalopathy. Brain and Development, 1998, 20, 530-535.	1.1	25
275	Duplication of proteolipid protein gene: A possible major cause of Pelizaeus-Merzbacher disease. Pediatric Neurology, 1997, 17, 125-128.	2.1	28
276	Arylsulfatase A pseudodeficiency in Chinese. Human Genetics, 1996, 97, 148-149.	3.8	5
277	Glucose-6-phosphatase gene G327A mutation is common in Chinese patients with glycogen storage disease type la. Human Molecular Genetics, 1995, 4, 1095-1096.	2.9	30
278	Cytogenetic study of mentally retarded children in Taipei. Journal of Biomedical Science, 1994, 1, 100-104.	7.0	6
279	Hereditary progressive dystonia with marked diurnal fluctuation (Segawa syndrome) in Taiwan. Brain and Development, 1994, 16, 126-131.	1.1	8
280	Transfusion-acquired cytomegalovirus infection in children in a hyperendemic area. Journal of Medical Virology, 1992, 36, 49-53.	5.0	7